Sources: AB Science readies $70M IPO

Reuters is reporting that France's AB Science is preparing to float an IPO designed to raise $70 million. Quoting sources, Reuters says that Societe Generale has been tapped as the lead manager with Fortis as the co-manager. And if it all works according to plan, AB Science will have the first French biotech IPO since mid-2008. The developer has a veterinary cancer therapy on the market and is testing the same compound in humans. Report

Suggested Articles

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development. 

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.